Summit Global Investments’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.45M | Buy |
11,516
+638
| +6% | +$80.2K | 0.09% | 136 |
|
|
2025
Q1 | $1.2M | Sell |
10,878
-21,182
| -66% | -$2.34M | 0.09% | 138 |
|
|
2024
Q4 | $4.38M | Sell |
32,060
-21,517
| -40% | -$2.94M | 0.27% | 81 |
|
|
2024
Q3 | $6.17M | Sell |
53,577
-24,024
| -31% | -$2.77M | 0.39% | 54 |
|
|
2024
Q2 | $10.7M | Buy |
77,601
+28,124
| +57% | +$3.87M | 0.72% | 28 |
|
|
2024
Q1 | $6.82M | Buy |
49,477
+8,744
| +21% | +$1.21M | 0.51% | 46 |
|
|
2023
Q4 | $5.37M | Buy |
40,733
+10,696
| +36% | +$1.41M | 0.35% | 66 |
|
|
2023
Q3 | $3.38M | Buy |
30,037
+406
| +1% | +$45.7K | 0.23% | 96 |
|
|
2023
Q2 | $2.79M | Buy |
29,631
+646
| +2% | +$60.9K | 0.19% | 115 |
|
|
2023
Q1 | $2.93M | Buy |
28,985
+2,309
| +9% | +$234K | 0.23% | 105 |
|
|
2022
Q4 | $3.19M | Buy |
26,676
+14,979
| +128% | +$1.79M | 0.27% | 103 |
|
|
2022
Q3 | $1.24M | Buy |
+11,697
| New | +$1.24M | 0.11% | 174 |
|